ASPG and acute lymphoblastic leukemia: Even BCR-ABL1-like ALL shows 73 times more resistance to asparaginase, 1.6 times more resistance to daunorubicin, and demonstrates poor sensitivity to glucocorticoids compared to standard-risk ALL [55,56]; de novo and acquired resistance to chemotherapy is known to be a major cause of treatment failure.